EA202091112A1 - Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение - Google Patents

Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение

Info

Publication number
EA202091112A1
EA202091112A1 EA202091112A EA202091112A EA202091112A1 EA 202091112 A1 EA202091112 A1 EA 202091112A1 EA 202091112 A EA202091112 A EA 202091112A EA 202091112 A EA202091112 A EA 202091112A EA 202091112 A1 EA202091112 A1 EA 202091112A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
pharmaceutical compositions
socrystals
treatment
application
Prior art date
Application number
EA202091112A
Other languages
English (en)
Russian (ru)
Inventor
Бенджамин С. Лэйн
Чун-Хой Гу
Original Assignee
Аджиос Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Аджиос Фармасьютикалз, Инк. filed Critical Аджиос Фармасьютикалз, Инк.
Publication of EA202091112A1 publication Critical patent/EA202091112A1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13Dicarboxylic acids
    • C07C57/145Maleic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235Saturated compounds containing more than one carboxyl group
    • C07C59/245Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/265Citric acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
EA202091112A 2017-11-02 2018-11-02 Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение EA202091112A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762580501P 2017-11-02 2017-11-02
PCT/US2018/058930 WO2019090059A1 (en) 2017-11-02 2018-11-02 Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same

Publications (1)

Publication Number Publication Date
EA202091112A1 true EA202091112A1 (ru) 2020-07-23

Family

ID=64572453

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202091112A EA202091112A1 (ru) 2017-11-02 2018-11-02 Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение

Country Status (16)

Country Link
US (3) US11345677B2 (https=)
EP (1) EP3704101A1 (https=)
JP (3) JP7335877B2 (https=)
KR (2) KR20240166601A (https=)
CN (2) CN111527076B (https=)
AU (2) AU2018360827B2 (https=)
CA (1) CA3081535A1 (https=)
EA (1) EA202091112A1 (https=)
IL (2) IL305426B2 (https=)
MA (1) MA50526A (https=)
MX (2) MX2020004513A (https=)
PH (1) PH12020550462A1 (https=)
SG (1) SG11202003612VA (https=)
TW (2) TWI839131B (https=)
UA (1) UA127380C2 (https=)
WO (1) WO2019090059A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200085832A1 (en) * 2019-11-22 2020-03-19 Agios Pharmaceuticals, Inc. Deuterated analogs of an organic compound
AR123228A1 (es) 2020-08-12 2022-11-09 Servier Pharmaceuticals Llc Formas en estado sólido de un compuesto orgánico
WO2023192565A1 (en) 2022-03-31 2023-10-05 Servier Pharmaceuticals Llc Methods of treating enhancing brain tumors using combination therapy
AR133332A1 (es) 2023-07-25 2025-09-17 Servier Lab Sales, cocristales, composiciones farmacéuticas de los mismos, y métodos de tratamiento que implican los mismos
WO2025060940A1 (zh) * 2023-09-18 2025-03-27 贝达药业股份有限公司 突变型idh抑制剂化合物及其盐的固体形式
EP4538262A1 (en) 2023-10-12 2025-04-16 Sandoz Ag Cocrystals of vorasidenib
WO2025168757A1 (en) 2024-02-09 2025-08-14 Les Laboratoires Servier Process for the preparation of vorasidenib

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX382354B (es) * 2010-11-01 2025-03-13 Celgene Car Llc Compuestos heterocíclicos y usos de los mismos.
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
WO2015003360A2 (en) * 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use

Also Published As

Publication number Publication date
CN111527076A (zh) 2020-08-11
US20220363661A1 (en) 2022-11-17
SG11202003612VA (en) 2020-05-28
JP2021501766A (ja) 2021-01-21
JP2024113028A (ja) 2024-08-21
JP7335877B2 (ja) 2023-08-30
US20210198234A1 (en) 2021-07-01
EP3704101A1 (en) 2020-09-09
AU2024203186B2 (en) 2026-04-16
IL274123B2 (en) 2024-01-01
US11851417B2 (en) 2023-12-26
IL305426B2 (en) 2024-10-01
TWI796377B (zh) 2023-03-21
KR102731624B1 (ko) 2024-11-19
UA127380C2 (uk) 2023-08-02
MA50526A (fr) 2020-09-09
US11345677B2 (en) 2022-05-31
US20240343705A1 (en) 2024-10-17
WO2019090059A1 (en) 2019-05-09
CA3081535A1 (en) 2019-05-09
AU2018360827A1 (en) 2020-05-14
AU2024203186A1 (en) 2024-05-30
CN111527076B (zh) 2024-03-12
IL274123A (en) 2020-06-30
JP7499377B2 (ja) 2024-06-13
JP7780576B2 (ja) 2025-12-04
KR20240166601A (ko) 2024-11-26
AU2018360827B2 (en) 2024-02-22
TW201930285A (zh) 2019-08-01
PH12020550462A1 (en) 2021-03-22
IL305426B1 (en) 2024-06-01
MX2020004513A (es) 2020-09-17
JP2023093666A (ja) 2023-07-04
TW202337885A (zh) 2023-10-01
CN118359585A (zh) 2024-07-19
MX2022014792A (es) 2023-01-16
IL274123B1 (en) 2023-09-01
IL305426A (en) 2023-10-01
BR112020008598A2 (pt) 2021-01-26
KR20200095480A (ko) 2020-08-10
TWI839131B (zh) 2024-04-11

Similar Documents

Publication Publication Date Title
CY1125772T1 (el) Μακροκυκλικες ενωσεις για τη θεραπευτικη αντιμετωπιση νοσων
EA202091112A1 (ru) Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение
MX2023007212A (es) Formulaciones de pulverizacion de epinefrina.
MX391981B (es) Derivados de benzooxazol como inmunomoduladores.
EA201891203A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
EA201691845A1 (ru) Фармацевтические композиции терапевтически активных соединений
EA201890530A1 (ru) Конъюгаты антитела к dll3 и лекарственного средства и способы их применения
EA202090098A1 (ru) Фармацевтические композиции терапевтически активных соединений
EA201491330A1 (ru) Терапевтически активные соединения и способы их использования
EA201990043A1 (ru) Антибактериальные соединения
JO3735B1 (ar) مركبات ألكين بها استبدال رباعي واستخداماتها
EA201791516A1 (ru) Способы комбинированного лечения злокачественных опухолей
EA201790142A1 (ru) Лечение лейкоза ингибиторами гистондеацетилазы
EA201591925A1 (ru) Терапевтические композиции и их применение
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
EA201691918A1 (ru) Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения
EA201991196A1 (ru) Претерпевшие самосборку диблок-сополимеры, состоящие из pegmema и несущих лекарственное средство полимерных сегментов
TW201613578A (en) Pharmaceutical combinations
JOP20200242A1 (ar) مركبات البلاديينوليد واستخداماتها
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
EA201890457A1 (ru) Комбинации антитела против ox40 и модулятора tlr4 и их применение
JO3565B1 (ar) الأجسام المضادة لشبيه الأنجيوبوييتين– 4 وطرق استخدامها
WO2016029136A8 (en) 3-amidobenzamides and uses thereof for increasing cellular levels of a3g